Garuda Therapeutics

Dhvanit Shah, Ph.D., President and CEO 

Oct. 11 | 4:15pm | Rentschler ATMP Ballroom  

Cambridge, MA 


Our platform technology for generating self-renewing blood stem cells is poised to provide patients with rapid and broad access to consistent, durable, HLA-compatible transgene-free blood stem cell therapies. As the industry’s first off-the-shelf offering, Garuda’s technology has the potential to cure more than 70 diseases and eliminate dependency on donor or patient cells. 

By using this website you agree to accept our Privacy Policy and Terms & Conditions